- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Plasma membrane H -ATPase.
Displaying page 1 of 1.
| EudraCT Number: 2018-003042-16 | Sponsor Protocol Number: IIBSP-PTE-2018-35 | Start Date*: 2019-02-08 |
| Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
| Full Title: Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane... | ||
| Medical condition: Pterigyum | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
| Sponsor Name:AMsterdam UMC-AMC | ||
| Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
| Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-001258-82 | Sponsor Protocol Number: CFTRcysta1 | Start Date*: 2013-09-12 |
| Sponsor Name:European Institute for Cystic Fibrosis Research (IERFC) | ||
| Full Title: A phase II pilot clinical study of experimental research to evaluate the functional rescue of CFTR protein through proteostasis regulators | ||
| Medical condition: Cystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutations | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006953-41 | Sponsor Protocol Number: C08-002B | Start Date*: 2009-08-19 | |||||||||||
| Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | |||||||||||||
| Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS). | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000789-53 | Sponsor Protocol Number: VWFC-ECMO | Start Date*: 2017-03-09 | |||||||||||
| Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin | |||||||||||||
| Full Title: A pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation | |||||||||||||
| Medical condition: Von Willebrand Disease (VWD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003036-37 | Sponsor Protocol Number: ECMO-vWFC | Start Date*: 2017-10-27 | |||||||||||
| Sponsor Name:Tirol Kliniken GmbH | |||||||||||||
| Full Title: A double-blind, placebo-controlled pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygen... | |||||||||||||
| Medical condition: Von Willebrand Disease (VWD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-006952-23 | Sponsor Protocol Number: C08-002A | Start Date*: 2009-08-19 | |||||||||||
| Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | |||||||||||||
| Medical condition: Adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006954-17 | Sponsor Protocol Number: C08-003A | Start Date*: 2009-06-18 | |||||||||||
| Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | |||||||||||||
| Medical condition: Adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001590-25 | Sponsor Protocol Number: CC-10004-PSA-006 | Start Date*: 2013-10-03 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATI... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) ES (Completed) EE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006955-28 | Sponsor Protocol Number: C08-003B | Start Date*: 2009-08-19 | |||||||||||
| Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | |||||||||||||
| Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapysensitive Atypical Hemolytic-Uremic Syndrome (aHUS). | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
| Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
| Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
| Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001087-10 | Sponsor Protocol Number: ELA-0121 | Start Date*: 2022-11-21 | |||||||||||
| Sponsor Name:Stemline Therapeutics, Inc | |||||||||||||
| Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B... | |||||||||||||
| Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.